

2021

1. Iwami D, Matsumoto T, Ono K, Hotta K, Ota M, Chiba Y, Sasaki H, Hirose T, Higuchi H, Takada Y, Iwahara N, Murai S, Shinohara N: **Novel double-filtration plasmapheresis preserves fibrinogen while removing immunoglobulin-G antibodies before ABO blood type-incompatible kidney transplantation.** *Renal Replacement Therapy*. 2021 7 (1): doi: <https://doi.org/10.1186/s41100-021-00379-z>. [5y-IF: N/A]
2. Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H, Japan Urological Oncology Group: **Impact of the objective response to and number of cycles of platinum- based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.** *Int J Urol*. 2021 Dec; 28 (12): 1261-1267. [5y-IF: 3.011]
3. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N: **Primary renal leiomyosarcoma with a tumor thrombus in the inferior vena cava.** *IJU Case Rep*. 2021 Nov; 5 (1): 66-69. [5y-IF: N/A]
4. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: **Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?** *BJR Open*. 2021 Nov; 3 (1): 20210064. [5y-IF: N/A]
5. Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M, Japanese Urological Oncology Group: **Novel metastatic burden- stratified risk model in de novo metastatic hormone-sensitive prostate cancer.** *Cancer Sci*. 2021 Sep; 112 (9): 3616-3626. [5y-IF: 6.622]
6. Shoji T, Niida Y, Osawa T, Matsumoto R, Sakurai K, Suzuki M, Matsuno Y, Konno S: **Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex.** *Respir Med Case Rep*. 2021 Oct; 34: 101526. [5y-IF: N/A]

7. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, Shinohara N: **Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary tract urothelial carcinoma.** *IJU Case Rep.* 2021 Dec; **5** (2): 108-112. [5y-IF: N/A]

2022

1. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N: **Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning.** *Langenbecks Arch Surg.* 2022 Aug; **407** (5): 2123-2132. [5y-IF: 3.116]
2. Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y, Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N: **Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.** *Int J Urol.* 2022 Oct; **29** (10): 1140-1146. [5y-IF: 3.011]
3. Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuhara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M: **Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.** *Int J Urol.* 2022 Jul; doi: 10.1111/iju.14977. [5y- IF: 3.011]
4. Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, Shinohara N: **Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.** *Urol Oncol.* 2022 Jan; **40** (1): 13.e19-13.e27. [5y-IF: 3.011]

5. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N: **Outcomes of bacillus Calmette- Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era.** *Int J Urol.* 2022 Mar; **29** (3): 251-258. [5y-IF: 3.011]
6. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N: **Automatic assessment of laparoscopic surgical skill competence based on motion metrics.** *PLoS One.* 2022 Nov; **17** (11): e0277105. [5y-IF: 4.069]
7. Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe A, Shinohara N: **Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.** *PLoS One.* 2022 Mar; **17** (3): e0265230. [5y-IF: 4.069]
8. Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H, Japanese Urological Oncology Group: **Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node- positive prostate cancer.** *Cancer Sci.* 2022 Jul; **113** (7): 2386-2396. [5y-IF: 6.622]
9. Sugimoto M, Kato T, Tohi Y, Shimizu Y, Matsumoto R, Inoue T, Takezawa Y, Masui K, Sasaki H, Hirama H, Saito S, Egawa S, Kamoto T, Teramukai S, Kojima S, Kikuchi T, Kakehi Y: **Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.** *BMC Urol.* 2022 Sep; **22** (1): 151. [5y-IF: 2.317]
10. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari H, Abe T, Shinohara N, Kudo K: **Imaging findings of ovarian metastasis of primary renal cell carcinoma: A case report and literature review.** *Radiol Case Rep.* 2022 May; **17** (7): 2320-2327. [5y-IF: N/A]

11. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M: **Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study.** *Urol Oncol.* 2022 Feb; **40** (2): 56.e9-56.e15. [5y-IF: 3.099]
12. Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M: **Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.** *Int J Clin Oncol.* 2022 Jan; **27** (1): 194-201. [5y-IF: 3.467]
13. Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M: **Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS- JAPAN study.** *Jpn J Clin Oncol.* 2022 Jun; hyac092. [5y-IF: 2.864]
14. Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: **Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities.** *Urol Oncol.* 2022 Jan; **40** (1): 11.e17-11.e25. [5y-IF: 3.099]
15. Yamagata Y, Abe T, Iwahara N, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: **Metastatic neuroendocrine carcinoma of right adrenal glands successfully treated with laparoscopic adrenalectomy after multimodal therapy.** *IJU case reports.* 2022 July; doi: <https://doi.org/10.1002/iju5.12511>. [5y-IF: N/A]